Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAAShell Companies
+$0.00 today
- Market cap
- $264.62M
- Beta
- 0.00
- P/E (TTM)
- 36.7
- EPS (TTM)
- $0.29
Volume 0.00M
Average 0.11M
DMAA Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQ: DMAA
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns positive
Q1 FY2026 net change in cash was $8.75K, compared with -$428 a year earlier. Trailing-twelve-month net change in cash was $12.79K.
What to watch
Whether quarterly net change in cash holds near $8.75K or moves back toward the trailing-twelve-month quarterly average of $3.2K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 4.79K USD
- Year-over-year change
- +254.3%
- 1-year CAGR
- +254.3%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.79K | +254.3% |
| FY2024 | 2024-12-31 | 1.35K | — |
Net Change in Cash vs competitors
How DMAA compares with its peers on the latest reported figures
- DMAA's LTM Mar 2026 net change in cash of $12.79K is the smallest of the 10 companies compared; the peer median is $479.17K.
- Its year-over-year change of +174.6% is the 2nd highest of 4, against a peer median of -108.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | $1.33M | — | — | — | |
| FY2025 | $930.71K | -167.3% | +128.1% | — | |
OYSEOyster Enterprises II Acquisition Corp | FY2025 | $864.58K | — | — | — |
| LTM Mar 2026 | $558.09K | — | — | — | |
TACOUBerto Acquisition Corp. Unit | FY2025 | $544.64K | — | — | — |
| FY2025 | $544.64K | — | — | — | |
TACHTitan Acquisition Corp. | LTM Mar 2026 | $479.17K | +2821592.1% | — | — |
| LTM Mar 2026 | $463.43K | — | — | — | |
| LTM Mar 2026 | $43.3K | -108.5% | — | — | |
| LTM Mar 2026 | $12.79K | +174.6% | — | — | |
| Peer median (excluding DMAA) | $479.17K | -108.5% | +128.1% | — | |
Competitors are the stored peer set for DMAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | (479) | 3.97M |
| Depreciation & Amortization | 0 | 0 |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 0 | 0 |
| Change in Working Capital | 132 | 138.85K |
| Accounts Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Accounts Payables | 0 | 144.9K |
| Other Working Capital | 132 | (6.05K) |
| Other Non-Cash Items | (171.92K) | (4.65M) |
| Operating Cash Flow | (295) | (539.19K) |
| Capital Expenditures | 5 | 0 |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | 0 | 0 |
| Sales of Investments | 0 | 0 |
| Other Investing Activities | 0 | (231.15M) |
| Investing Cash Flow | 0 | (231.15M) |
| Debt Repayment | 502.21K | (900K) |
| Common Stock Issued | (328.6K) | 232.05M |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 1 | 543.97K |
| Financing Cash Flow | 173.62K | 231.69M |
| Effect of Forex Changes | 0 | 0 |
| Net Change in Cash | 1.35K | 4.79K |
| Free Cash Flow | (295) | (539.19K) |
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAA
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.